With more cha-ching, will PDUFA V satisfy on the ba-bling?

The smooth sailing the Prescription Drug User Fee Act (PDUFA) reauthorization process experienced this past year – with the legislation getting through Congress with rare bipartisan support and little opposition in record time – does not necessarily mean there will be calm waters ahead for the US FDA, which must now follow through on the negotiated commitments it made, albeit with a few dollars more in its pocket and some added authorities and flexibility.

The smooth sailing the Prescription Drug User Fee Act (PDUFA) reauthorization process experienced this past year – with the legislation getting through Congress with rare bipartisan support and little opposition in record time – does not necessarily mean there will be calm waters ahead for the US FDA, which must now follow through on the negotiated commitments it made, albeit with a few dollars more in its pocket and some added authorities and flexibility.

Forget about the price tag. Even with the expected more than $4 billion over five years in user fees, making...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.